January 3rd, 2026
Centering Community Wisdom:
Research and Quality Led by PLWH
Dr. Karla Torres
Research and Quality Improvements for PLWH
March 7th 2026
Review of HIV Aging Symposium – Palm Springs, February 2026
- Jason Cuneo, The Center, POZabilities, “Heart Disease in PLWH”
- Jen Lothridge, POZabilties, “Women Living with HIV”
- Jerry L Turner, Consortium – POZabilities, “Aging and Cognition in PLWH”
CROI Update
Conference on Retroviruses and Opportunistic Infections
The largest global scientific conference on HIV
- Dr. Karla Torres
- Dr. Joseph Caperna
April 4th, 2026
Representation of People of Color Living with HIV in Clinical Research
- Inspiring a new era of inclusive research
- Good Science is Inclusive Science
Dr. Renarda Jones – Diverse Research NOW
Representation Matters in Clinical Trials!
New Study for People Living with HIV
- Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
Dr. David Grelotti, UCSD Owen Clinic, UC San Diego AntiViral Research Center.
https://clinicaltrials.ucsd.edu/trial/NCT06705478
May 2nd, 2026
Advancements in HIV Treatment and Prevention with Dr. Lucas Hill
- The shift from daily oral medications to less frequent dosing options
- New once-daily pill combinations, including bictegravir/lenacapavir (called BIC/LEN) and doravirine/islatravir, currently in development
- Weekly oral HIV treatments in Phase 2 clinical trials
- Long-acting injectable options, including broadly neutralizing antibodies (bNAbs) combined with lenacapavir for potential every-6-month treatment intervals
- Considerations surrounding two-drug versus three-drug HIV treatment regimens
- Future PrEP options, including potential every-4-month and every-6-month injectable therapies
HIV ARV review Dr Hill UCSD May 2026
Lorraine Cheng, PsyD candidate,
shared information regarding an upcoming mental health survey study for people living with HIV in San Diego County. She is currently completing final coordination steps with local organizations and plans to return soon to begin participant recruitment.
The survey:
- Takes approximately 20–30 minutes to complete
- Offers a $10 Visa gift card for participation
- Is available in English and Spanish
- Seeks to gather quantitative data on mental health factors, including stigma, access to care, and social support
- Aims to recruit 75–150 participants from diverse demographic group
Monthly Science Detailed Update May 2026
June 6th, 2026
ACTHIV 2026 Update and the UCSD Annual Symposium on Women’s Health
Original SDHIVC research presented at each conference.
Led by Jason Cuneo and Wanda London
July 11th, 2026
“Long-Acting Medicine for HIV: A presentation for People Living with HIV”
Randall McDavid, MS, FNP-C, FNP-BC, AAHIVE — Medical Liaison, ViiV
Q & A time with:
Larry Roberts, PharmD, MPH Community Engagement Account Manager, ViiV Healthcare
Patient Ambassador, TBA
Wanda London, SW, WLWH
“I hear the sounds of the war drums”
https://www.youtube.com/watch?v=x2XoPsNzvpU
Monthly Update July 2026
Links for additional information
Cabenuva vs. Biktarvy – Understanding Your Options
Cabenuva Women Centered Review
August 1st, 2026
Using AI Alongside Your Provider for HIV Care
Dr. Michael Majeski, PsyD, who has provided mental health care to people living with HIV in San Diego for over four decades, will focus on mental health in PLWH.
Dr. Joe Caperna, MD, Clinical Professor, UCSD
CUATRO: CAB and RPV Ultra Long-Acting for Treatment of People with HIV
- Comparing the every-2-month CAB/RPV LA to the every-4-month CAB/RPV ULA. Switch off oral ART to injectable.
- Participants cannot have ever received any long-acting ARVs.
- The project is looking to recruit mostly diverse populations, so spots for white men are limited unless they are under 24.
- Participants are paid $100 per visit.
A5424: Menopausal Hormone Therapy for Women Living with HIV
- Women 40–60 who experience vasomotor symptoms and are on suppressive ART.
- No changes to ART.
- Two arms, 2:1 randomization. Arm 1 is estradiol transdermal gel plus oral progesterone daily for 12 weeks. Arm 2 is placebos to match.
- Daily symptom diaries, weekly telephone check-ins, and 5 in-person visits.
- $50 per visit, $25 per phone call, $250 for diaries.
September 5th, 2026
Review of AIDS 2026, International AIDS Conference, Rio de Janeiro
What’s New in HIV Highlights from IAS 2026 Rio
Presenter: Jason Cuneo, BA